You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 28, 2024

Patent: 8,562,980


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,562,980
Title:Stable digestive enzyme compositions
Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
Inventor(s): Ortenzi; Giovanni (Monza, IT), Marconi; Marco (Cinisello Balsamo, IT), Mapelli; Luigi (Milan, IT)
Assignee: Aptalis Pharma Limited (Wicklow, IE)
Application Number:13/019,856
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Scope and Claims of United States Patent 8,562,980: Stable Digestive Enzyme Compositions

Introduction

United States Patent 8,562,980, titled "Stable Digestive Enzyme Compositions," is a patent that addresses the formulation and stabilization of digestive enzymes, which are crucial for treating or preventing disorders associated with digestive enzyme deficiencies. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Patent Overview

The patent, issued to the inventors, describes compositions and methods for stabilizing digestive enzymes, such as pancrelipase, which are essential for breaking down food components in the alimentary tract. The key focus is on maintaining the enzymatic activity of these enzymes over long-term storage and use[4].

Claims Analysis

Independent Claims

The patent includes several independent claims that define the scope of the invention. Here are some of the key claims:

  • Claim 1: This claim describes a composition comprising at least one digestive enzyme, where the composition has a moisture content of about 3% or less and a water activity of about 0.6 or less. This ensures the stability of the enzymes[4].

  • Claim 2: This claim specifies a composition where the digestive enzyme exhibits a loss of activity of no more than about 15% after six months of accelerated stability testing, further emphasizing the stability aspect[4].

  • Claim 3: This claim outlines a dosage form, such as a tablet or capsule, filled with the composition of the present invention. The composition may include the digestive enzyme coated with an enteric polymer and optionally at least one inorganic material[4].

Dependent Claims

Dependent claims build upon the independent claims and provide additional specifics:

  • Claim 4: This claim details the method of preparing the composition, including coating particles of the digestive enzyme in an atmosphere with controlled moisture content[4].

  • Claim 5: This claim describes the package containing the composition, including a sealed container made of moisture-resistant material and a desiccant to maintain the stability of the enzymes[4].

Scope of the Invention

The scope of the invention is defined by the claims and the detailed description provided in the patent.

Stability of Digestive Enzymes

The primary focus is on stabilizing digestive enzymes to maintain their enzymatic activity over time. This is achieved through specific formulations and packaging that control moisture content and water activity[4].

Application and Use

The compositions are designed for treating or preventing disorders associated with digestive enzyme deficiencies. The patent also outlines methods for administering these compositions to mammals in need thereof[4].

Patent Landscape

Related Patents and Applications

The patent landscape for digestive enzyme compositions is extensive, with numerous patents and applications focusing on various aspects of enzyme stability, formulation, and delivery.

  • International Patent Databases: Searching international patent databases such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and World Intellectual Property Organization (WIPO) can reveal similar inventions and ongoing research in this field[1].

  • Prior Art: The patent cites prior art related to pharmaceutical compositions, lipase activity, and other digestive enzymes. Understanding this prior art is crucial for assessing the novelty and non-obviousness of the invention[4].

Competitive Analysis

Competitive analysis involves identifying other patents and products in the market that address similar needs. For instance, other patents may focus on different stabilization methods or delivery systems for digestive enzymes.

Legal and Regulatory Aspects

Subject Matter Eligibility

The USPTO provides guidance on the subject matter eligibility of claims in patent applications, which is crucial for ensuring that the claims of US Patent 8,562,980 align with current legal standards. The 2024 guidance update on patent subject matter eligibility is particularly relevant[5].

Patent Litigation and Enforcement

The feasibility of enforcing this patent, especially in the context of potential small claims patent courts, is an important consideration. Studies and reports by the Administrative Conference of the United States (ACUS) on small claims patent courts can provide insights into the legal and practical considerations involved[2].

Metrics for Patent Scope

Research on patent scope metrics, such as independent claim length and independent claim count, can help in evaluating the breadth and clarity of the claims in US Patent 8,562,980. These metrics have been shown to have explanatory power for several correlates of patent scope, including patent maintenance payments and forward citations[3].

Practical Implications

Manufacturing and Storage

The practical implications of this patent include the manufacturing process and storage conditions that must be adhered to in order to maintain the stability of the digestive enzymes. This involves controlled environments and specific packaging materials[4].

Clinical Use

The compositions described in the patent are intended for clinical use, and their stability ensures that they remain effective over their shelf life. This is critical for patients relying on these enzymes for digestive health.

Key Takeaways

  • Stability Focus: The patent emphasizes the stabilization of digestive enzymes through controlled moisture content and water activity.
  • Formulation and Delivery: The invention includes specific formulations and delivery systems, such as enteric coatings and moisture-resistant packaging.
  • Clinical Application: The compositions are designed for treating or preventing digestive enzyme deficiencies.
  • Legal and Regulatory Compliance: The patent must comply with current subject matter eligibility guidelines and consider the broader legal landscape.
  • Competitive Landscape: Understanding related patents and applications is essential for competitive analysis.

FAQs

Q: What is the primary focus of US Patent 8,562,980? A: The primary focus is on stabilizing digestive enzymes to maintain their enzymatic activity over time.

Q: How does the patent ensure the stability of digestive enzymes? A: The patent ensures stability through specific formulations with controlled moisture content and water activity, as well as specialized packaging.

Q: What are the clinical applications of the compositions described in the patent? A: The compositions are designed for treating or preventing disorders associated with digestive enzyme deficiencies.

Q: How does this patent fit into the broader patent landscape for digestive enzymes? A: It is part of a larger landscape that includes numerous patents and applications focusing on various aspects of enzyme stability and delivery.

Q: What legal considerations are important for this patent? A: Ensuring compliance with subject matter eligibility guidelines and understanding the implications of potential small claims patent courts are crucial legal considerations.

More… ↓

⤷  Subscribe

Details for Patent 8,562,980

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. COTAZYM pancrelipase Capsule, Delayed Release 020580 December 09, 1996 ⤷  Subscribe 2027-02-20
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 April 30, 2009 ⤷  Subscribe 2027-02-20
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 June 10, 2011 ⤷  Subscribe 2027-02-20
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 March 14, 2013 ⤷  Subscribe 2027-02-20
Digestive Care, Inc. PERTZYE pancrelipase Capsule, Delayed Release 022175 May 17, 2012 ⤷  Subscribe 2027-02-20
Digestive Care, Inc. PERTZYE pancrelipase Capsule, Delayed Release 022175 October 06, 2016 ⤷  Subscribe 2027-02-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 8,562,980

Country Patent Number Estimated Expiration
South Africa 200905630 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2008102264 ⤷  Subscribe
United States of America 8562981 ⤷  Subscribe
United States of America 8562979 ⤷  Subscribe
United States of America 8562978 ⤷  Subscribe
United States of America 8293229 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.